切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2016, Vol. 05 ›› Issue (03) : 153 -157. doi: 10.3877/cma.j.issn.2095-3232.2016.03.007

所属专题: 文献

临床研究

门静脉血栓形成对内镜下食管静脉曲张套扎术临床疗效的影响
陈伶君1, 郭云蔚1, 林颖1, 郑丰平1,()   
  1. 1. 510630 广州,中山大学附属第三医院消化内科
  • 收稿日期:2016-03-08 出版日期:2016-06-10
  • 通信作者: 郑丰平
  • 基金资助:
    广东省科技计划项目(2008B030301038)

Influence of portal vein thrombosis on clinical efficacy of endoscopic esophageal variceal ligation

Lingjun Chen1, Yunwei Guo1, Ying Lin1, Fengping Zheng1,()   

  1. 1. Department of Gastroenterology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2016-03-08 Published:2016-06-10
  • Corresponding author: Fengping Zheng
  • About author:
    Corresponding author: Zheng Fengping, Email:
引用本文:

陈伶君, 郭云蔚, 林颖, 郑丰平. 门静脉血栓形成对内镜下食管静脉曲张套扎术临床疗效的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2016, 05(03): 153-157.

Lingjun Chen, Yunwei Guo, Ying Lin, Fengping Zheng. Influence of portal vein thrombosis on clinical efficacy of endoscopic esophageal variceal ligation[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2016, 05(03): 153-157.

目的

探讨门静脉血栓形成(PVT)对内镜下食管静脉曲张套扎术(EVL)治疗肝硬化食管静脉曲张破裂出血(EVH)疗效的影响。

方法

回顾性分析2005年1月至2014年12月在中山大学附属第三医院接受内镜下EVL治疗且随访超过6个月的314例肝硬化EVH患者临床资料。所有患者均签署知情同意书,符合医学伦理学规定。根据治疗时有否PVT将患者分为PVT组和对照组。其中PVT组72例,男61例,女11例;平均年龄(50±11)岁。对照组242例,男206例,女36例;年龄(47±11)岁。比较两组患者的临床疗效,分析PVT与食管静脉曲张(EV)消除率、EV再出血率的关系。两组EVL疗程数比较采用t检验,率的比较采用χ2检验。PVT与EV消除率、EV再出血率的关系采用单因素logistic回归分析。

结果

PVT组发生急性EVH 36例,对照组115例,经EVL治疗后两组急诊止血率均为100%。PVT组EV消除率为76%(55/72),明显低于对照组的90%(218/242) (χ2=9.166,P<0.05)。PVT组EVL疗程数为(3.4±1.6)个,明显多于对照组的(2.8±1.1)个(t=3.065,P<0.05)。PVT组EV再出血率为36%(26/72),明显高于对照组的21%(51/242) (χ2=6.779,P<0.05)。PVT是影响患者EV消除率的危险因素(OR=0.356,95%CI:0.179~0.709,P<0.05),亦是影响患者EV再出血的危险因素(OR=2.383,95%CI:1.354~4.196,P<0.05)。

结论

PVT是影响内镜下EVL治疗肝硬化EVH患者EV消除率及再出血率的危险因素。

Objective

To explore the influence of portal vein thrombosis (PVT) on the clinical efficacy of endoscopic esophageal variceal ligation (EVL) in cirrhotic patients with esophagogastric variceal hemorrhage (EVH).

Methods

Clinical data of 314 cirrhotic patients with EVH who underwent endoscopic EVL and were followed up for more than 6 months in the Third Affiliated Hospital of Sun Yat-sen University between January 2005 and December 2014 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. The patients were divided into the PVT group and the control group according to whether they had PVT during treatment. Among the 72 patients in the PVT group, 61 were males and 11 were females with the mean age of (50±11) years old. Among the 242 patients in the control group, 206 were males and 36 were females with the mean age of (47±11) years old. The clinical efficacy of two groups was compared, and the correlation between PVT and the elimination rate of esophageal varices (EV) as well as the recurrent bleeding rate of EV was analyzed. The number of EVL treatment period in two groups was compared using t test and the rate was compared using Chi-square test. Univariate logistic regression analysis was conducted for the correlation between PVT and the elimination rate, recurrent bleeding rate of EV.

Results

Thirty-six patients in the PVT group and 115 patients in the control group developed acute EVH. After EVL, the emergency hemostatic rate of both groups was 100%. The elimination rate of EV in the PVT group was 76%(55/72), significantly lower than 90%(218/242) in the control group (χ2=9.166, P<0.05). The number of EVL treatment period in the PVT group was 3.4±1.6, significantly more than 2.8±1.1 in the control group (t=3.065, P<0.05). The recurrent bleeding rate of EV in the PVT group was 36%(26/72), significantly higher than 21%(51/242) in the control group (χ2=6.779, P<0.05). PVT was a risk factor for both the elimination rate of EV (OR=0.356, 95%CI: 0.179-0.709, P<0.05) and the recurrent bleeding rate of EV (OR=2.383, 95%CI: 1.354-4.196, P<0.05).

Conclusion

PVT is a risk factor for both the elimination rate of EV and the recurrent bleeding rate of EV in cirrhotic patients with EVH treated by endoscopic EVL.

表1 不同部位PVT对内镜下EVL治疗肝硬化EVH患者临床疗效的比较
表2 不同程度PVT对内镜下EVL治疗肝硬化EVH患者临床疗效的比较
[1]
de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol, 2010, 53(4):762-768.
[2]
de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752.
[3]
Kumar A, Sharma P, Arora A. Review article: portal vein obstruction--epidemiology, pathogenesis, natural history, prognosis and treatment[J]. Aliment Pharmacol Ther, 2015, 41(3): 276-292.
[4]
Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667.
[5]
中华医学会消化内镜学分会.食管胃静脉曲张内镜下诊断和治疗规范试行方案(2003年)[J].中华消化内镜杂志,2004,21(3):149-151.
[6]
Nusrat S, Khan MS, Fazili J, et al. Cirrhosis and its complications: evidence based treatment[J]. World J Gastroenterol, 2014, 20(18):5442-5460.
[7]
Hwang JH, Shergill AK, Acosta RD, et al. The role of endoscopy in the management of variceal hemorrhage[J]. Gastrointest Endosc, 2014, 80(2):221-227.
[8]
Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic non-cirrhotic non-tumoral portal vein thrombosis[J]. Hepatology, 2016, DOI: 10.1002/hep.28466[Epub ahead of print].
[9]
Manzano-Robleda Mdel C, Barranco-Fragoso B, Uribe M, et al. Portal vein thrombosis: what is new?[J]. Ann Hepatol, 2015, 14(1):20-27.
[10]
Ljubicić N, Bisćanin A, Nikolić M, et al. A randomized-controlled trial of endoscopic treatment of acute esophageal variceal hemorrhage: N-butyl-2-cyanoacrylate injection vs. variceal ligation[J]. Hepatogastroenterology, 2011, 58(106):438-443.
[11]
Luo X, Wang Z, Tsauo J, et al. Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding[J]. Radiology, 2015, 276(1):286-293.
[12]
Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key[J]. Hepatology, 2010, 51(6):1894-1896.
[13]
La Mura V, Nicolini A, Tosetti G, et al. Cirrhosis and portal hypertension: the importance of risk stratification, the role of hepatic venous pressure gradient measurement[J]. World J Hepatol, 2015, 7(4):688-695.
[14]
Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: the role of hepatic venous pressure gradient measurement[J]. World J Hepatol, 2015, 7(3):607-615.
[15]
Dell'Era A, Iannuzzi F, Fabris FM, et al. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation[J]. Dig Liver Dis, 2014, 46(2):152-156.
[16]
Luz GO, Maluf-Filho F, Matuguma SE, et al. Comparison between endoscopic sclerotherapy and band ligation for hemostasis of acute variceal bleeding[J]. World J Gastrointest Endosc, 2011, 3(5):95-100.
[17]
Ouakaa-Kchaou A, Kharrat J, Mir K, et al. Variceal band ligation in the prevention of variceal bleeding: a multicenter trial[J]. Saudi J Gastroenterol, 2011, 17(2):105-109.
[18]
Dai C, Liu WX, Jiang M, et al. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis[J]. World J Gastroenterol, 2015, 21(8):2534-2541.
[19]
Yoshida H, Tajiri T, Mamada Y, et al. Comparison of characteristics of recurrent esophageal varices after endoscopic ligation versus endoscopic ligation plus sclerotherapy[J]. Hepatogastroenterology, 2004, 51(56):457-461.
[20]
Triantos C, Kalafateli M. Endoscopic treatment of esophageal varices in patients with liver cirrhosis[J]. World J Gastroenterol, 2014, 20(36):13015-13026.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 王卫东. 贲门周围血管离断与左膈下静脉的保留[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 464-464.
[3] 叶美妮, 刘思嘉, 臧玉玮, 刘云建. 肝硬化门静脉血栓形成的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 379-384.
[4] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[5] 贺健, 张骊, 王洪海, 蒋文涛. 肝移植术后脾功能亢进转归及治疗研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 310-314.
[6] 王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[7] 王浩, 艾克拜尔·艾力, 麦麦提艾力·麦麦提明, 李义亮, 克力木·阿不都热依木. 不同检查方法对巨大食管裂孔疝合并胃食管反流病的诊断价值及各检查指标间的相关性分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 494-500.
[8] 王飞, 陈政, 余德才, 曹亚娟. 原发性肝癌合并门静脉高压症的微创手术治疗[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 306-310.
[9] 蔡艺丹, 方坚, 张志强, 陈莉, 张世安, 夏磊, 阮梅, 李东良. 经颈静脉肝内门体分流术对肝硬化门脉高压患者肠道菌群及肝功能的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 285-293.
[10] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[11] 丁亚琴, 方旭, 戴彦成. 基于紧密型医联体的“一免三优先政策”在基层消化道肿瘤筛查中的应用探讨[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 481-484.
[12] 梁艳娉, 陈燕柔, 梁运啸, 白飞虎, 吴斌, 王省. 华南地区门静脉高压食管胃静脉曲张出血内镜治疗现状调研分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 390-395.
[13] 崔健, 夏青, 林云, 李光玲, 李心娜, 王位. 血小板与淋巴细胞比值、免疫球蛋白、心肌酶谱及心电图对中老年肝硬化患者病情及预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 400-406.
[14] 秦相清, 朱陈, 张海银. 构建诺模图模型预测肝硬化食管胃底静脉曲张出血的风险[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 330-335.
[15] 刘燚隆, 党荣广, 艾蓉, 张凯. 肝硬化合并静脉曲张出血患者内镜治疗后再出血风险的模型建立与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 336-342.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?